What's new in neuro-oncology? Recent advances in medulloblastoma

European Journal of Paediatric Neurology

Volumn 7, Issue 2, 2003, Pages 53-66

  Ellison, David W ^a   Clifford, Steven C ^a   Gajjar, Amar ^b   Gilbertson, Richard J ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPAMINE; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GROWTH FACTOR RECEPTOR; IFOSFAMIDE; IMATINIB; LOMUSTINE; MELPHALAN; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATINUM DERIVATIVE; PROCARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; SONIC HEDGEHOG PROTEIN; TERATOGENIC AGENT; THIOTEPA; UNCLASSIFIED DRUG; VINCRISTINE; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CHILDHOOD CANCER; CHROMOSOME ABERRATION; DRUG DESIGN; DRUG MEGADOSE; DRUG TARGETING; GENE IDENTIFICATION; GENETIC ANALYSIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MEDULLOBLASTOMA; MOLECULAR GENETICS; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION;

EID: 0037273964     PISSN: 10903798     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1090-3798(03)00014-X     Document Type: Review

References (64)

1. Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 1983;42:1-15.
2. Russo C, Pellarin M, Tingby O, et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 1999;86:331-9.
3. Nicholson JC, Ross FM, Kohler JA, et al. Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours. Br J Cancer 1999;80:1322-31.
4. Rostomily RC, Bermingham-McDonogh O, Berger MS, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res 1997;57:3526-31.
5. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: (2002) 215-25; discussion 226-229
6. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203-6.
7. Eberhart CG, Kaufman WE, Tihan T, et al. Apoptosis, neuronal maturation, and neurotrophin expression within medulloblastoma nodules. J Neuropathol Exp Neurol 2001;60:462-9.
8. Giangaspero F, Perilongo G, Fondelli MP, et al. Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 1999;91:971-7.
9. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002;94:552-60.
10. Giangaspero F, Rigobello L, Badiali M, et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 1992;16:687-93.
11. Brown HG, Kepner JL, Perlman EJ, et al. Large cell/anaplastic medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000;59:857-65.
12. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36-44.
13. Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997;57:2085-8.
14. Schofield D, West DC, Anthony DC, et al. Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas. Am J Pathol 1995;146:472-80.
15. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nature Genet 2002;31:306-10.
16. Gilbertson R. Paediatric embryonic brain tumours. biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 2002;38:675-85.
17. Goussia AC, Bruner JM, Kyritsis AP, et al. Cytogenetic and molecular genetic abnormalities in primitive neuroectodermal tumors of the central nervous system. Anticancer Res 2000;20:65-73.
18. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002;28:257-82.
19. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
20. Kleihues P, Schauble B, zur Hausen A, et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997;150:1-13.
21. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839-47.
22. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85:841-51.
23. Taylor MD, Mainprize TG, Rutka JT, et al. Medulloblastoma in a child with Rubenstein-Taybi syndrome: case report and review of the literature. Pediatr Neurosurg 2001;35:235-8.
24. Rogers L, Pattisapu J, Smith RR, et al. Medulloblastoma in association with the Coffin-Siris syndrome. Childs Nerv Syst 1988;4:41-4.
25. Raffel C, Jenkins RB, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842-5.
26. Vorechovsky I, Tingby O, Hartman M, et al. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 1997;15:361-6.
27. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-54.
28. Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-13.
29. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001;61:513-6.
30. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58:1798-803.
31. Wolter M, Reifenberger J, Sommer C, et al. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997;57:2581-5.
32. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 2000;27:44-51.
33. Huang H, Mahler-Araujo BM, Sankila A, et al. APC mutations in sporadic medulloblastomas. Am J Pathol 2000;156:433-7.
34. Zurawel RH, Chiappa SA, Allen C, et al. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998;58:896-9.
35. Koch A, Waha A, Tonn JC, et al. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001;93:445-9.
36. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000;59:333-7.
37. Davis FG, Freels S, Grutsch J, et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998;88:1-10.
38. Gajjar A, Sanford RA, Bhargava R, et al. Medulloblastoma with brain stem involvement: the impact of gross total resection on outcome. Pediatr Neurosurg 1996;25:182-7.
39. Spoudeas HA. Growth and endocrine function after chemotherapy and radiotherapy in childhood. Eur J Cancer 2002; 38: (2002) 1748-59; discussion 1760-1761
40. Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992;10:1390-6.
41. Deutsch M, Thomas PR, Krischer J, et al. Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study. Pediatr Neurosurg 1996;24:167-76.
42. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 1999;17:2127-36.
43. Ris MD, Packer R, Goldwein J, et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 2001;19:3470-6.
44. Mulhern RK, Kepner JL, Thomas PR, et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 1998;16:1723-8.
45. Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995;25:166-78.
46. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomised study of pre-radiation chemotherapy vs radiotherapy alone for Non-metastatic (M0-1) medulloblastoma The SIOP/UKCCSG PNET-3 study. J Clin Oncol 2003; in press.
47. Kortmann RD, Kuhl J, Timmermann B, et al. Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT 91. Int J Radiat Oncol Biol Phys 2000;46:269-79.
48. Hughes EN, Shillito J, Sallan SE, et al. Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer 1988;61:1992-8.
49. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994;81:690-8.
50. Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001;19:2696-704.
51. Graham ML, Herndon JE 2nd, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997;15:1814-23.
52. Finlay JL, Goldman S, Wong MC, et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol 1996;14:2495-503.
53. Guruangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998;16:2486-93.
54. Mahoney Jr. DH, Strother D, Camitta B, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 1996;14:382-8.
55. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
56. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002;1:31-6.
57. Hernan R, Fasheh R, Calabrese, et al. ERBB2 upregulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003;1:140-8.
58. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nature Genet 2001;29:143-52.
59. Weiss WA, Israel M, Cobbs C, et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 2002;21:7453-63.
60. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000;406:1005-9.
61. Chen JK, Taipale J, Cooper MK, et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002;16:2743-8.
62. Gilbertson RJ, Perry RH, Kelly PJ, et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272-80.
63. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001;85:705-12.
64. Gilbertson RJ, Clifford SC, MacMeekin W, et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res 1998;58:3932-41.